Aktis Oncology to Participate in Upcoming September Investor Conferences
BOSTON, Sept. 10, 2025 — Aktis Oncology, Inc., a clinical-stage oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, announced that Matthew Roden, PhD, President and Chief Executive Officer, and other members of the Aktis Oncology leadership team will participate in the following September investor conferences.
Conference Participation
| Conference | Date | Location |
|---|---|---|
| Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit | Thursday, September 11, 2025 | New York, N.Y. |
| Bank of America Healthcare Trailblazers Private Company Conference | Wednesday, September 17, 2025 | Everett, Mass. |
About Aktis Oncology
Aktis Oncology, Inc. is a clinical-stage oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for large patient populations not addressed by existing platform technologies. Aktis’ most advanced pipeline program targets Nectin-4, a tumor-associated antigen found in urothelial and other solid cancers. Founded and incubated by MPM BioImpact, Aktis has developed a proprietary miniprotein radioconjugate platform to generate tumor-targeting agents with properties ideal for alpha radiopharmaceuticals.
Designed to maximize tumor killing through high penetration followed by internalization and retention in cancer cells, Aktis’ miniprotein radioconjugates are intended to clear quickly from normal organs and tissues, thereby maximizing anticancer activity while minimizing side effects. The Aktis platform is isotope-agnostic and enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Aktis also has a strategic collaboration with Eli Lilly and Company to leverage its miniprotein platform to develop novel radioconjugates outside of Aktis’ proprietary pipeline.
To learn more about Aktis Oncology, visit www.aktisoncology.com.
Media Contact
Elizabeth Grufferman
ICR Healthcare
(203) 682-4726
Email: [email protected]
Investor Contact
Peter Vozzo
ICR Healthcare
(443) 213-0505
Email: [email protected]
Source: Aktis Oncology